Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
In this research study we will start by looking for the highest dose of pyrimethamine that
can be given safely to CLL patients without severe or unmanageable side effects. This dose
will then be used for a larger Phase II study to assess the efficacy of pyrimethamine for the
treatment of CLL/SLL. Pyrimethamine is an antibiotic that is used for the treatment of
certain infections. Previous research studies have shown that pyrimethamine may target a
protein in tumor cells, called STAT3, which may be important for the growth of chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) cells. Pyrimethamine can kill
CLL/SLL cells in the laboratory, and we are therefore undertaking this study to assess
whether pyrimethamine will result in clinical benefit or tumor responses in CLL in patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Lymphoma Research Foundation